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background: Major vascular complications (VC) after transcatheter aortic valve replacement (TAVR) in surgically inoperable aortic stenosis (AS) 
patients are common and are associated with unfavorable outcomes. However, the frequency and impact of VC with the use of the newer low-profile 
SAPIEN-XT valve and delivery system is unknown.
Methods: In PARTNER 2, 553 inoperable AS patients were randomly assigned and were treated with transfemoral (TF) TAVR using either the 
commercially-approved SAPIEN (22 or 24-F delivery sheaths) vs. the newer SAPIEN-XT (18 or 19-F delivery sheaths) systems. The 1-year rates of VC 
(modified VARC-2 definitions), predictors, and impact on mortality were assessed.
results: All VC (major and minor) at 30-days were 22.5% with SAPIEN vs. 15.6% with SAPIEN-XT (HR 1.47, CI 1.00-2.17, p=0.04). Importantly, 
major VC at 30-days were also increased after SAPIEN compared with SAPIEN-XT (15.5% vs. 9.6%, HR 1.63, CI 1.00-2.64, p=0.04). The most 
common causes of major VC were significant vascular dissections (43.9%), vascular perforations (20.7%), and severe access site hematomas 
(12.5%), all of which were significantly reduced with SAPIEN-XT. Major and minor VC at 30-days were less frequent in men compared to women 
(14.1% vs. 24.0%, HR 0.57, CI 0.38-0.85, p<0.01), and patients with major VC had lower BSA (1.74 with VC vs. 1.84 without VC, p<0.01). Patients 
with major VC were more likely to experience increased bleeding events at 30-days (27.8% vs. 8.0%, p<0.01), particularly disabling bleeds (15.2% 
vs. 2.9%, p<0.01) and bleeds requiring transfusion (20.8% vs. 6.1%, p<0.01). There was no statistical difference in 1-year all-cause mortality in 
patients with major VC between SAPIEN and SAPIEN-XT (25.5% vs. 37.9%, p=0.26). However, in a Cox regression model, major VC with both SAPIEN 
and SAPIEN-XT were equally associated with increased all-cause mortality at 1-year (HR 1.64, CI 1.03-2.62, p=0.0356).
conclusions: Vascular complications after TAVR are still frequent and are associated with adverse clinical outcomes (increased bleeding events 
and 1-year mortality). However, with the new lower-profile SAPIEN-XT system, the rates of overall and major VC are importantly reduced.
